| KAI Pharmaceuticals Announces Advancement of KAI-4169 Clinical Program into a ... - Business Wire (press release) |
|
|
Business Wire (press release) Results obtained in the study will be used to select the appropriate dosing regimen for further development of KAI-4169 for the chronic management of SHPT in ESRD patients. Previous Phase 1 data demonstrated that single IV doses of KAI-4169 were safe |